鉴于治疗方案的进步，内假体重建治疗转移性骨病（MBD）的指征可能会越来越明显。本研究的目的是回顾MBD患者进行EPR的适应症、移植物和患者生存率。在两个中心进行了一项研究，对1992年至2022年进行了下肢MBD的EPR患者进行了回顾。该研究检查了手术数据、移植物存活率、患者生存率和移植物失效方式。共纳入115名患者，随访中位数为14.9个月（95%置信区间[CI]：9.2-19.3），生存期为19.4个月（95% CI：13.6-26.1）。最常见的诊断是肾癌（34/115，29.6%），最常见的部位是股骨近端（43/115，37.4%）。适应症包括：实际骨折（58/115，50.4%），潜在骨折（30/115，26.1%）和手术固定失败（27/115，23.5%）。移植物失效较少（10/115，8.7%）。进行EPR治疗手术固定失败的患者更可能拥有肾癌或肺癌（p = 0.006）。EPR治疗最常用于肾癌患者，并且用于相对较有利的生存患者。在23.5%的情况下，EPR用于手术固定失败的患者，强调了预测生存模型的重要性。EPR可以是MBD患者的可靠和持久的手术选择。 © 2023 The Authors. Journal of Surgical Oncology published by Wiley Periodicals LLC.

Given advances in therapies, endoprosthetic reconstruction (EPR) in metastatic bone disease (MBD) may be increasingly indicated. The objectives were to review the indications, and implant and patient survivorship in patients undergoing EPR for MBD.A review of patients undergoing EPR for extremity MBD between 1992 and 2022 at two centers was performed. Surgical data, implant survival, patient survival, and implant failure modes were examined.One hundred fifteen patients were included with a median follow-up of 14.9 months (95% confidence interval [CI]: 9.2-19.3) and survival of 19.4 months (95% CI: 13.6-26.1). The most common diagnosis was renal cell carcinoma (34/115, 29.6%) and the most common location was proximal femur (43/115, 37.4%). Indications included: actualized fracture (58/115, 50.4%), impending fracture (30/115, 26.1%), and failed fixation (27/115, 23.5%). Implant failure was uncommon (10/115, 8.7%). Patients undergoing EPR for failed fixation were more likely to have renal or lung cancer (p = 0.006).EPRs were performed most frequently for renal cell carcinoma and in patients with a relatively favorable survival. EPR was indicated for failed previous fixation in 23.5% of cases, emphasizing the importance of predictive survival modeling. EPR can be a reliable and durable surgical option for patients with MBD.© 2023 The Authors. Journal of Surgical Oncology published by Wiley Periodicals LLC.